The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Which patients with mesothelioma benefit most from checkpoint inhibitors?
Cornedine Jannette de Gooijer, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, explores current biomarkers of response to checkpoint inhibitors such as nivolumab and ipilimumab in patients with mesothelioma. Pathological subtype has typically been a reliable biomarker, where non- epithelioid mesothelioma responds better to checkpoint inhibitors, as demonstrated in the Phase III BEAT-meso (NCT03762018) and IND227 (NCT02784171) trials. Whilst epithelioid subtypes have not responded well to immunotherapy, findings from the Phase II PEMMELA trial (NCT04287829) suggest they have a potential role in the second line setting. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
